Request Demo

Last update 08 May 2025

CD8 x KIR family

Last update 08 May 2025

Basic Info

Related Targets

CD8KIR family

Drugs associated with CD8 x KIR family

MTX-101 (Mozart Therapeutics)

Target

CD8 x KIR family

Mechanism

CD8 stimulants [+1]

Active Org.

Mozart Therapeutics, Inc.

Originator Org.

Mozart Therapeutics, Inc.

Active Indication

Celiac Disease [+2]

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with CD8 x KIR family

NCT06324604

/ RecruitingPhase 1

Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients

First in human study to understand the potential side effects of MTX-101, how long MTX-101 lasts in the human body, and how MTX-101 affects specific human immune cells.

Start Date13 Jun 2024

Sponsor / Collaborator

Mozart Therapeutics, Inc.

100 Clinical Results associated with CD8 x KIR family

100 Translational Medicine associated with CD8 x KIR family

0 Patents (Medical) associated with CD8 x KIR family

228

Literatures (Medical) associated with CD8 x KIR family

01 Jun 2025·Infectious Diseases Now

HLA-A*03 may confer protection against long COVID through an enhanced immune response

Article

Author: Tomás, Cristina ; Martinez-Rodriguez, Rodrigo ; Gimeno-Arias, Lourdes ; Pelaez, Ana ; Bernal, Enrique ; Alcaraz, M J ; García, Elisa ; Moreno, Marta ; Gómez, Jose M ; Muñoz, Angeles ; Minguela, Alfredo ; Ruiz-Lorente, Inmaculada ; Pons-Fuster, Eduardo ; Martínez-Sánchez, María V ; Ceballos, Diana

BACKGROUNDThe COVID-19 pandemic has led to widespread infection, with a significant subset of patients developing persistent symptoms known as Long COVID. Understanding the genetic factors influencing Long COVID susceptibility and severity is crucial for development of targeted interventions.OBJECTIVEThis study aimed to evaluate the impact of HLA alleles, KIR receptors, and their interactions on the development of Long COVID in patients from southeastern Spain having contracted COVID-19 during the early 2020 pandemic wave.METHODSA cross-sectional prospective study enrolled 153 COVID-19 patients. Three months post-infection, HLA-A, -B, -C, KIR genotyping and immunological variables were analyzed using serum and blood samples. Long COVID was diagnosed three years post- infection based on persistent symptoms.RESULTSAmong the participants, 71 developed Long COVID. HLA-A*03 was less frequent in Long COVID compared to non-Long COVID patients (10.7 % vs. 30.5 %, p = 0.001). Patients with HLA-A*03 had a higher percentage of CD8⁺ T cells than patients with other allotypes (33.6 ± 13.4 % vs 28.7 ± 10.8 %, p = 0.033) and showed lower expression of KIR2DL1(1265 ± 547 vs 1465 ± 414 MFI, p = 0.031) and KIR3DL1 (300.6 ± 125.0 vs 398.9 ± 131.0 MFI, p = 0.047). Moreover, NK cells in HLA-A*03 patients showed lower expression of the TIGIT inhibitory receptor (73.7 ± 12.2 % vs 78.2 ± 10.8 %, p = 0.046).CONCLUSIONHLA-A*03 may play a protective role against Long COVID, potentially through enhanced immune responses involving CD8⁺ T cells and NK cells. Further research in larger, diverse cohorts is needed to validate these findings and to refine personalized medicine strategies for managing COVID-19 sequelae.

18 Mar 2025·British Journal of Dermatology

Comment on ‘Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder’ by Wobser et al.

Article

Author: Louveau, Baptiste ; Ram-Wolff, Caroline ; Mancini, Maxence ; De Masson, Adèle ; Mourah, Samia ; Jouenne, Fanélie ; Battistella, Maxime

Identifying pathognomonic features that differentiate primary cutaneous acral CD8+ T-cell lymphoproliferative disorder (TLPD) from other CD8+ aggressive lymphomas is a major concern. Doing so can facilitate diagnosis and allow clinicians to optimize clinical management. In this context, we read with great interest the article from Wobser et al., which proposed a molecular characterization of five cutaneous acral CD8+ TLPDs and identified KIR3DL1 alterations in addition to PIK3R1 alterations. To broaden this spectrum, we propose genomic profiling of six cutaneous acral CD8+ TLPDs from our database and identify alterations related to oncogenic pathways such as the AKT pathway and the Janus kinase–signal transducer and activator of transcription protein pathway. We also confirm the decreased mRNA expression of KIR3DL1 in this setting.

01 Feb 2025·Nature Immunology

Differential roles of human CD4+ and CD8+ regulatory T cells in controlling self-reactive immune responses

Article

Author: Ghanizada, Mustafa ; Capasso, Robson ; Mallajosyula, Vamsee ; Chen, Xin ; Davis, Mark M ; Sola, Elsa ; Kathuria, Karan Raj

AbstractHere we analyzed the relative contributions of CD4+ regulatory T cells expressing Forkhead box protein P3 (FOXP3) and CD8+ regulatory T cells expressing killer cell immunoglobulin-like receptors to the control of autoreactive T and B lymphocytes in human tonsil-derived immune organoids. FOXP3 and GZMB respectively encode proteins FOXP3 and granzyme B, which are critical to the suppressive functions of CD4+ and CD8+ regulatory T cells. Using CRISPR–Cas9 gene editing, we were able to achieve a reduction of ~90–95% in the expression of these genes. FOXP3 knockout in tonsil T cells led to production of antibodies against a variety of autoantigens and increased the affinity of influenza-specific antibodies. By contrast, GZMB knockout resulted in an increase in follicular helper T cells, consistent with the ablation of CD8+ regulatory T cells observed in mouse models, and a marked expansion of autoreactive CD8+ and CD4+ T cells. These findings highlight the distinct yet complementary roles of CD8+ and CD4+ regulatory T cells in regulating cellular and humoral responses to prevent autoimmunity.

News (Medical) associated with CD8 x KIR family

21 Jun 2023

·www.prnewswire.com

Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel CD8 Treg Network Modulator for Treatment of Autoimmune Disease, at FOCIS 2023 Annual Meeting

SEATTLE, June 21, 2023 /PRNewswire/ -- Mozart Therapeutics, a leading developer of CD8 Treg Modulators for the treatment of autoimmune and inflammatory disease, today announced the presentation of preclinical pharmacologic and tolerability data for MTX-101, a bispecific autoimmune checkpoint inhibitor, at the Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2023). Presented findings include: MTX-101 is well-tolerated following a single dose in humanized mice MTX-101 selectively acts on CD8 Treg in blood and tissues and does not cause activation of other immune cells nor an increase of pro-inflammatory cytokines; MTX-101 possesses a favorable and antibody-like pharmacokinetic profile. The poster "Pre-clinical Pharmacologic and Tolerability Characterization of MTX-101, a Novel KIR x CD8 Targeting Bispecific CD8 Treg Modulator" (Abstract #1517124) can be accessed from the Mozart Therapeutics website. About MTX-101 MTX-101 is a bispecific CD8 Treg Modulator targeting inhibitory KIR and CD8 expressed on regulatory CD8 T cells. This autoimmune checkpoint inhibitor aims to restore regulatory CD8 T cell function, acting early in the autoimmune disease process to halt downstream inflammation and prevent further complication. The initial therapeutic focus for MTX-101 is gastro-intestinal autoimmune disorders. About Mozart Therapeutics Mozart Therapeutics is focused on developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory CD8 T regulatory cell network. The company is headquartered in Seattle, WA. For more information visit and follow the company on LinkedIn @Mozart-tx. SOURCE Mozart Therapeutics

ImmunotherapyAACR

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis